Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Prog Pediatr Cardiol. 2021 Nov 2;63:101460. doi: 10.1016/j.ppedcard.2021.101460

Fig. 1.

Fig. 1.

Comparison of major approaches for genetic correction for DMD. Four different antisense oligonucleotides (AON) have been approved for use in the US. These target specific DMD mutations. Adeno-associated viral gene therapy is being investigated in ongoing clinical trials and aims to produce micro-dystrophin in skeletal and cardiac muscle. Gene editing is also contemplated for DMD; gene editing has been tested in preclinical models, including a large animal model for DMD.